Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Gastroenterology ; 141(3): 918-28, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21699774

ABSTRACT

BACKGROUND & AIMS: CD46 is a C3b/C4b binding complement regulator and a receptor for several human pathogens. We examined the interaction between CD46 and Helicobacter pylori (a bacterium that colonizes the human gastric mucosa and causes gastritis), peptic ulcers, and cancer. METHODS: Using gastric epithelial cells, we analyzed a set of H pylori strains and mutants for their ability to interact with CD46 and/or influence CD46 expression. Bacterial interaction with full-length CD46 and small CD46 peptides was evaluated by flow cytometry, fluorescence microscopy, enzyme-linked immunosorbent assay, and bacterial survival analyses. RESULTS: H pylori infection caused shedding of CD46 into the extracellular environment. A soluble form of CD46 bound to H pylori and inhibited growth, in a dose- and time-dependent manner, by interacting with urease and alkyl hydroperoxide reductase, which are essential bacterial pathogenicity-associated factors. Binding of CD46 or CD46-derived synthetic peptides blocked the urease activity and ability of bacteria to survive in acidic environments. Oral administration of one CD46 peptide eradicated H pylori from infected mice. CONCLUSIONS: CD46 is an antimicrobial agent that can eradicate H pylori. CD46 peptides might be developed to treat H pylori infection.


Subject(s)
Anti-Bacterial Agents/pharmacology , Gastric Mucosa/metabolism , Helicobacter pylori/drug effects , Membrane Cofactor Protein/pharmacology , Urease/drug effects , Urease/metabolism , Animals , Anti-Bacterial Agents/therapeutic use , Cell Line , Disease Models, Animal , Dose-Response Relationship, Drug , Epithelial Cells/cytology , Epithelial Cells/metabolism , Epithelial Cells/microbiology , Gastric Mucosa/cytology , Gastric Mucosa/microbiology , Helicobacter Infections/drug therapy , Helicobacter Infections/metabolism , Helicobacter pylori/growth & development , Helicobacter pylori/metabolism , Humans , Membrane Cofactor Protein/metabolism , Membrane Cofactor Protein/therapeutic use , Mice , Mice, Mutant Strains , Peroxiredoxins/drug effects , Peroxiredoxins/metabolism , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...